HSBC downgraded Biogen Inc. (BIIB) from Hold to Reduce with a price target of $143 due to concerns about royalty streams and core business challenges affecting future earnings and growth. Despite this, recent operational developments include LEQEMBI’s inclusion in China’s Commercial Insurance Innovative Drug List, enhancing market access.

Biogen Inc. (BIIB) and Stoke Therapeutics presented positive data for zorevunersen, an investigational treatment for Dravet syndrome, showcasing progress in rare neurological disorders. While BIIB reports clinical and market access advancements, challenges like declining royalty streams and legacy revenue drivers may hinder earnings growth and margin expansion, per HSBC’s analysis.

Biogen Inc. (BIIB) is a prominent biotechnology company specializing in treatments for neurological and neurodegenerative diseases. Despite potential investment risks, some AI stocks are deemed to offer higher returns and shorter time frames for growth. For more information on promising AI stocks with significant upside potential, read our report on the cheapest AI stock.

Read more at Yahoo Finance: HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress